GlassScriptPhysician profile
Maggie Chen
NPI 1700476835
$10,292.34
in general payments reported to CMS, 2019-2025
26 companies · $3,203 in 2025
The $3,203 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $187 · 2022: $1,438 · 2023: $2,398 · 2024: $3,066 · 2025: $3,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,551 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,550.53 |
| Education | $116.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,313.50 | 2021-2025 | |
| Genzyme Corporation | $1,182.08 | 2022-2025 | |
| Amgen INC. | $1,048.52 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $884.10 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $732.89 | 2021-2025 | Tremfya |
| Leo Pharma INC. | $530.98 | 2022-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $503.20 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Pfizer INC. | $500.66 | 2022-2025 | |
| Ucb, INC. | $472.52 | 2022-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $429.37 | 2024-2025 | Nemluvio, Aklief, Oracea |
| Dermavant Sciences, INC. | $288.21 | 2023-2024 | Vtama |
| Lilly USA, LLC | $239.56 | 2022-2025 | Ebglyss, Taltz |
| Novartis Pharmaceuticals Corporation | $232.40 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $221.84 | 2022-2023 | Sotyktu |
| Incyte Corporation | $203.94 | 2022-2024 | Opzelura |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $115.11 | 2024-2025 | Zoryve |
| Ibsa Pharma INC. | $104.17 | 2022 | |
| Sanofi-Aventis U.S. LLC | $89.95 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.94 | 2023 | Arazlo, Jublia |
| Novo Nordisk INC | $42.54 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.01 | 2024 | Farxiga |
| Lnhc, INC | $23.79 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.72 | 2023 | Cyltezo |
| Botanix Sb INC | $16.70 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $14.70 | 2024 | Nuzyra |
| Sandoz INC. | $13.94 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maggie Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.